Fernando Rosso

Fernando Rosso

Auto-generated profile, based on publicly available information

Fernando Rosso

Departamento de Infectología, Fundación Valle del Lili, Cali, Colombia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Transplantation
Verified
Journal Article
Closed access
NSNina Singh
Nina Singh
ALAjit P Limaye
Ajit P Limaye
GFGraeme Forrest
Graeme Forrest
NSNasia Safdar
Nasia Safdar
PMPatricia Munoz
Patricia Munoz
SHShahid Husain
Shahid Husain
The efficacy of the combination of voriconazole and caspofungin when used as primary therapy for invasive aspergillosis in organ transplant recipients has not been defined. Transplant recipients who received voriconazole and caspofungin (n=40) as primary therapy for invasive aspergillosis (proven or probable) in a prospective multicenter study between 2003 and 2005 were compared to a control group comprising a cohort of consecutive transplant recipients between 1999 and 2002 who had received a lipid formulation of AmB as primary therapy (n=47). In vitro antifungal testing of Aspergillus isolates to combination therapy was correlated with clinical outcome. Survival at 90 days was 67.5% (27/40) in the cases, and 51% (24/47) in the control group (HR 0.58, 95% CI, 0.30–1.14, P=0.117). However, in transplant recipients with renal failure (adjusted HR 0.32, 95% CI: 0.12–0.85, P=0.022), and in those with A. fumigatus infection (adjusted HR 0.37, 95% CI: 0.16–0.84, P=0.019), combination therapy was independently associated with an improved 90-day survival in multivariate analysis. No correlation was found between in vitro antifungal interactions of the Aspergillus isolates to the combination of voriconazole and caspofungin and clinical outcome. Combination of voriconazole and caspofungin might be considered preferable therapy for subsets of organ transplant recipients with invasive aspergillosis, such as those with renal failure or A. fumigatus infection.

22 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MVMaría Virginia Villegas
María Virginia Villegas
CPChristian J Pallares
Christian J Pallares
KEKevin Escandón
Kevin Escandón
CHCristhian Hernández-Gómez
Cristhian Hernández-Gómez
ACAdriana Correa
Adriana Correa
MGManuel Guzmán-Blanco
Manuel Guzmán-Blanco
Infections caused by carbapenem-resistant Enterobacteriaceae are a public health problem associated with higher mortality rates, longer hospitalization and increased healthcare costs. We carried out a study to describe the characteristics of patients with carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE bloodstream infection (BSI) from Latin American hospitals and to determine the clinical impact in terms of mortality and antibiotic therapy. Between July 2013 and November 2014, we conducted a multicenter observational study in 11 hospitals from 7 Latin American countries (Argentina, Colombia, Ecuador, Guatemala, Mexico, Peru, Venezuela). Patients with BSI caused by Enterobacteriaceae were included and classified either as CPE or non-CPE based on detection of blaKPC, blaVIM, blaIMP, blaNDM and blaOXA-48 by polymerase chain reaction. Enrolled subjects were followed until discharge or death. Demographic, microbiological and clinical characteristics were collected from medical records. Both descriptive and inferential statistics were used to analyze the information. A total of 255 patients with Enterobacteriaceae BSI were included; CPE were identified in 53 of them. In vitro non-susceptibility to all screened antibiotics was higher in the patients with CPE BSI, remaining colistin, tigecycline and amikacin as the most active drugs. Combination therapy was significantly more frequent in the CPE BSI group (p < 0.001). The most common regimen was carbapenem + colistin or polymyxin B. The overall mortality was 37% (94/255). Overall and attributable mortality were significantly higher in patients with CPE BSI (p < 0.001); however, we found that patients with CPE BSI who received combination therapy and those who received monotherapy had similar mortality. After multivariate adjustment, CPE BSI (adjusted odds ratio [aOR] 4; 95% confidence interval [CI] 1.7–9.5; p = 0.002) and critical illness (aOR 6.5; 95% CI 3.1–13.7; p < 0.001) were independently associated with in-hospital mortality. This study provides valuable data on the clinical characteristics and mortality risk factors in patients with CPE BSI. We determined that CPE infection is an independent mortality predictor and thus Latin American hospitals should perform campaigns on prevention and control of CPE BSI.

1 September 2001 in Psychosomatics
Verified
Journal Article
Closed access
HRHernan G. Rincon
Hernan G. Rincon
MGMarcela Granados
Marcela Granados
JUJurgen Unutzer
Jurgen Unutzer
MGMonica Gomez
Monica Gomez
RDRon Duran
Ron Duran
PEPatricia Echeverri
Patricia Echeverri

1 March 2008 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
FRFernando Rosso
Fernando Rosso
JLJessica T. Les
Jessica T. Les
AAAlejandro Agudelo
Alejandro Agudelo
CVCarlos Villalobos
Carlos Villalobos
JCJosé A. Chaves
José A. Chaves
JMJosé G. Montoya
José G. Montoya
The aim of this study was to determine the prevalence of toxoplasma antibodies among pregnant women in Cali, Colombia. In 2005, 955 pregnant women were tested for IgG and IgM antibodies and sociodemographic information was collected. Their average age was 25.1 years, overall IgG seroprevalence 45.8% (95% CI: 41.8%, 48.2%), IgM 2.8% (95% CI: 1.5%, 3.6%). Seroprevalence increased significantly with age, 39.0% in 14 to 19 years to 55.3% in 30 to 39 years (P = 0.001). There was a significant trend toward a higher seroprevalence in the lower socioeconomic strata (SES) (low: 49.0%, high: 29%, P = 0.004). The increase in seroprevalence by age was more significant in the lower socioeconomic strata (P = 0.002). Our results suggest a higher prevalence when compared with those of the national 1980 (33–37.6%) survey. In contrast to reports from other regions of the world, Cali has not seen a decrease in T. gondii seroprevalence over the past 25 years.

1 September 2005 in Clinics in Perinatology
Verified
Journal Article
Closed access
JMJose G. Montoya
Jose G. Montoya
FRFernando Rosso
Fernando Rosso

18 January 2007 in Mycoses
Verified
Journal Article
Closed access
PDF file
DHDora Ho
Dora Ho
JLJason D. Lee
Jason D. Lee
FRFernando Rosso
Fernando Rosso
JMJose G. Montoya
Jose G. Montoya